The Role of Late‐Night Salivary Cortisol in the Assessment of Endocrine Remission in Patients With Cushing's Disease After Pituitary Radiotherapy
Clinical Endocrinology · 2025
DOI: 10.1111/cen.15270 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Ukasha Habib und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Unit and Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hydrocortisone, Pituitary ACTH Hypersecretion, Saliva. Die Arbeit nennt 33 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Context
Pituitary radiotherapy (RT) is used for persistent/recurrent Cushing's disease (CD) after pituitary surgery. The utility of late‐night salivary cortisol (LNSC) in evaluating endocrine remission after RT is unclear.
Objective
To identify the clinical characteristics and outcomes of patients with CD after RT, in endocrine remission based on normal LNSC (group 1) or 24 h urinary free cortisol (UFC; group 2). Design and Setting Retrospective cohort, observational study in academic medical centre. Patients (16−86 years old, n = 75) with CD who underwent RT were studied; group 1 ( n = 16), group 2 ( n = 18), and 41 patients not in remission. Outcome measures included within‐group and between‐group changes (group 1 vs. group 2) in clinical characteristics, endocrine data and time to remission.
Results
Seventy‐five patients with CD, aged (median [range]: 50 years [16, 86], 71% female, BMI: 34.7 kg/m 2 [19.1, 62.5], 63% with macroadenomas) underwent RT and 34 (45.3%) entered endocrine remission, including 16 (21.3%) in group 1 and 18 (24%) in group 2 (median: 56 months). From RT to remission, there were decreases in BMI (group 1: −3.9 ± 0.7 kg/m 2 , p = 0.0001; group 2: −5.2 ± 1.9 kg/m 2 , p = 0.0123) and systolic blood pressure (group 1: −7.9 ± 3.9 mmHg, p = 0.03; group 2: −10.1 ± 4.5 mmHg ( p = 0.008). There were no between‐group differences in BMI, blood pressure, HbA1c, number of antihypertensive or antihyperglycemic agents, UFC, median time to remission, recurrence risk.
Conclusion
In patients with CD following RT, LNSC appears to be clinically equivalent to UFC in the assessment of endocrine remission. These patients can be followed with LNSC, which is easier for patients to collect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroendocrine Unit and Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Beverly M K Biller, Nicholas A Tritos
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Habib, U., Shih, H. A., Biller, B. M. K., & Tritos, N. A. (2025). The Role of Late‐Night Salivary Cortisol in the Assessment of Endocrine Remission in Patients With Cushing's Disease After Pituitary Radiotherapy. Clinical Endocrinology. https://doi.org/10.1111/cen.15270
Vancouver
Habib U, Shih HA, Biller BMK, Tritos NA. The Role of Late‐Night Salivary Cortisol in the Assessment of Endocrine Remission in Patients With Cushing's Disease After Pituitary Radiotherapy. Clinical Endocrinology. 2025. doi:10.1111/cen.15270
BibTeX
@article{Habib2025,
author = {Habib, Ukasha and Shih, Helen A and Biller, Beverly M K and Tritos, Nicholas A},
title = {The Role of Late‐Night Salivary Cortisol in the Assessment of Endocrine Remission in Patients With Cushing's Disease After Pituitary Radiotherapy},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.15270}
}
EUVIMED